TY - JOUR
T1 - Combination pharmacotherapy for stopping smoking
T2 - What advantages does it offer?
AU - Ebbert, Jon O.
AU - Hays, J. Taylor
AU - Hurt, Richard D.
N1 - Funding Information:
This project was supported by the National Cancer Institute Award (CA 138417Z). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. The funding organization had no role in the preparation, review or approval of the manuscript.
Funding Information:
JOE has no conflicts of interest to disclose. JTH has received research funding from Pfizer. RDH has served on advisory boards for Pfizer.
PY - 2010
Y1 - 2010
N2 - Globally, tobacco kills almost 5 million people around the world annually. Seven first-line pharmacotherapies are currently available and recommended by the United States Public Health Service (USPHS) clinical practice guideline for treating tobacco dependence, all of which have been proven to be effective for increasing tobacco abstinence rates when used as monotherapy. However, not all smokers are able to quit with single-drug therapy. Some smokers may benefit from combination therapy that includes the simultaneous use of different nicotine replacement therapies (NRTs) or medications with different mechanisms of action (e.g. NRT and bupropion). Combination therapy with different types of NRT may provide a therapeutic advantage by increasing serum nicotine concentrations, and combination therapy with different drugs may capitalize on synergy obtained from two different mechanisms of action. However, controversy exists regarding this approach. Available data suggests that combination therapy may increase abstinence rates compared with monotherapy. However, the cost effectiveness of this approach has not been clearly demonstrated.
AB - Globally, tobacco kills almost 5 million people around the world annually. Seven first-line pharmacotherapies are currently available and recommended by the United States Public Health Service (USPHS) clinical practice guideline for treating tobacco dependence, all of which have been proven to be effective for increasing tobacco abstinence rates when used as monotherapy. However, not all smokers are able to quit with single-drug therapy. Some smokers may benefit from combination therapy that includes the simultaneous use of different nicotine replacement therapies (NRTs) or medications with different mechanisms of action (e.g. NRT and bupropion). Combination therapy with different types of NRT may provide a therapeutic advantage by increasing serum nicotine concentrations, and combination therapy with different drugs may capitalize on synergy obtained from two different mechanisms of action. However, controversy exists regarding this approach. Available data suggests that combination therapy may increase abstinence rates compared with monotherapy. However, the cost effectiveness of this approach has not been clearly demonstrated.
UR - http://www.scopus.com/inward/record.url?scp=77951044898&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951044898&partnerID=8YFLogxK
U2 - 10.2165/11536100-000000000-00000
DO - 10.2165/11536100-000000000-00000
M3 - Comment/debate
C2 - 20394453
AN - SCOPUS:77951044898
SN - 0012-6667
VL - 70
SP - 643
EP - 650
JO - Drugs
JF - Drugs
IS - 6
ER -